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ABSTRACT
Objective: The objective of this selective EBM review is to determine whether or not
Sofosbuvir plus Ribavirin is safer and more effective than Peginterferon plus Ribavirin
for treatment of chronic Hepatitis C Virus infection in treatment-naïve patients.
Study Design: Systematic review of three English language primary studies, published in
2013.
Data Sources: Three randomized control trials, two of which are open-label, activecontrolled and one that is double-blind, placebo-controlled, comparing Sofosbuvir and
Ribavirin versus other chronic HCV modalities found via PubMed in peer-reviewed
journals.
Outcomes Measured: Safety was measured by self-reported adverse events, routine
laboratory tests, physical exams, vital signs, and electrocardiography and graded using
the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse
Events. Efficacy was determined by sustained virological response at 12 or 24 weeks
post-treatment (SVR12 and SVR24, respectively), which is classified as a HCV RNA
concentration below the limit of detection of 15 IU/mL or 25 IU/mL
Results: Gane, et al5 compared the treatment effects of 400mg Sofosbuvir and Ribavirin
(RBV) with that of Sofosbuvir plus RBV and Peginterferon (PEG) for 12 weeks in
patients with chronic HCV. Analysis resulted in an equal incidence of SVR24, but with
less adverse events in the experimental group. In Lawitz, Lalezari, et al6, patients
received 12 weeks with either 400mg Sofosbuvir, RBV, and PEG or placebo, PEG, and
RBV. SVR24 was higher in the Sofosbuvir group, however more adverse events of
fatigue were reported compared to the placebo group. Lawitz, Mangia, et al7 examined
the difference in treatment with 12 weeks of 400mg Sofosbuvir and RBV versus 24
weeks of PEG and RBV. Statistical analysis showed an equal rate of SVR12 between the
two groups, yet treatment with Sofosbuvir was safer.
Conclusions: It can be deduced from these three RCTs that Sofosbuvir plus RBV is
safer, yet, statistically, nearly equal in efficacy to treatment with PEG and RBV. Given
that PEG is a weekly injection with many unfavorable side effects, it would be more
beneficial to receive treatment with Sofosbuvir and RBV for treatment of chronic HCV
infection
Key Words: Hepatitis C, Sofosbuvir, treatment
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INTRODUCTION
Hepatitis C Virus (HCV) is an infectious RNA virus that invades the liver and is
transmitted primarily via exposure to infected blood, such as through intravenous drug abuse.1
Following an acute HCV infection, approximately 85% of cases become chronic, or when the
infection lasts greater than 3-6 months. 1, 2 This paper evaluates three randomized control trials
(RCTs) – two of which are open-label, active-controlled and one which is double-blind, placebocontrolled – comparing the safety and efficacy of Sofosbuvir and Ribavirin in the treatment of
chronic HCV.
The Center for Disease Control and Prevention (CDC) has estimated that chronic HCV
infection affects 3.2 million people in the United States alone.2 In 2011, it was projected that the
total healthcare cost associated with HCV infection was an average of $6.5 billion.3 Of those
infected with HCV, 75-85% will become a chronic infection, 60-70% will develop chronic liver
disease, 5-20% will develop cirrhosis, and 1-5% will die.2 Additionally, chronic HCV infection
can increase one’s chance of developing hepatocellular carcinoma and, due in part to its high
prevalence in the population, is the leading cause for liver transplantation.4
Unfortunately, there is no vaccine available to protect against HCV, only initiation of
preventative measures. Once infected, a person with HCV will usually be asymptomatic unless
severe liver disease and consequences ensue.2 Furthermore, during the acute phase, liver
function tests may be elevated, but once the HCV becomes chronic, the levels may normalize.1, 2
HCV infection, then, may only be exposed on routine laboratory screening.4 HCV infection is
determined by detection of anti-HCV antibodies through enzyme immunoassay (EIA). The
HCV can be further quantified by its RNA concentration through polymerase chain reaction
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(PCR).1 There are 6 major genotypes of HCV that are recognized, with genotype 1 being the
most common.2
The mainstay of treatment for chronic HCV infection has been a combination of
anywhere from one to three different drugs. The most utilized method is treatment with
Peginterferon-alfa 2a (PEG), a weekly subcutaneous injection, for 24-48 weeks.5 Not only does
PEG carry many side effects such as cytopenia and flu-like symptoms, but also many patients are
reluctant, or even unable, to adhere to the once weekly injections. 5 Although PEG can be
administered as a monotherapy, efficacy is rather low. The nucleoside inhibitor Ribavirin is used
as an adjunctive treatment, boosting the effectiveness of PEG and other therapies. Even with the
combination of ribavirin, however, the sustained virologic response (SVR) rate may be anywhere
from 45-80%, depending upon the HCV genotype. In the presence of liver disease or other
comorbidities, the SVR may be even lower.1
Newer drugs used to combat chronic HCV include the protease inhibitors Telaprevir and
Boceprevir, both of which were approved by the FDA in 2011. Although either of these drugs in
combination with PEG and ribavirin increased the efficacy of treatment to a SVR rate from 6675% in genotype 1 patients, effective in other genotypes has not been studied. Additionally,
dosing schedules, drug interactions, and side effects of these drugs have limited their extensive
use in chronic HCV treatment.6
A nucleotide polymerase inhibitor, Sofosbuvir, is the newest drug on the market for the
treatment of chronic HCV infection. FDA approved in December 2013, Sofosbuvir can be given
as a once daily oral dose and is thought to be safer and more effective and efficient than the
current treatment modalities.
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OBJECTIVE
The objective of this selective EBM review is to determine whether or not Sofosbuvir
plus Ribavirin is safer and more effective than Peginterferon plus Ribavirin for treatment of
chronic Hepatitis C Virus in treatment-naïve patients.

METHODS
Specific criteria were utilized in the selection of studies to establish as much parallel as
possible for proper comparison. The populations studied included previously untreated men and
women 18 years of age or older with chronic HCV infection. All three interventions included
the once-daily oral administration of Sofosbuvir 400mg and Ribavirin (RBV). In one study, the
intervention also included a once-weekly injection of PEG. For the two interventions of
Sofosbuvir plus RBV, one study compared it to treatment with the addition of PEG and the other
study compared it to PEG plus RBV. The third intervention, Sofosbuvir plus PEG and RBV,
was compared to a placebo plus PEG and RBV. The three studies included in this systematic
review were randomized control trials (RCTs), each measuring both safety and efficacy. Two of
the RCTs were open-label, active-controlled and the other one was double-blind, placebocontrolled.
Research was done by the author using the key words “Sofosbuvir,” “chronic HCV,” and
“HCV treatment” via the PubMed database. All articles were in English and published in peerreviewed journals in 2013. Articles were chosen according to their relevance to the clinical
question with outcomes that were patient oriented (POEMs)
Inclusion criteria contained studies that were RCTs and included patients who were 18
years and older with chronic HCV infection (Table 1). Exclusion criteria included significant
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comorbidities, such as Hepatitis B infection or Human Immunodeficiency Virus (HIV), and
previous treatment for their HCV infection (Table 1). Statistics reported in the studies included
sustained virologic response (SVR) rate, 95% confidence interval (CI), and p-values. The author
calculated relative risk reduction (RRR), absolute risk increase (ARI), absolute risk reduction
(ARR), numbers needed to harm (NNH), and numbers needed to treat (NNT).

Table 1: Demographics and characteristics of included studies
Type

# of
pts

Age
(yrs)

Gane,
et al5
2013

RCT

21

18+

≥18 y/o; Tx naïve;
Chronic HCV
infection (serum HCV
RNA level, >50,000
IU/mL)

Lawitz,
Lalezari
et al6
2013

RCT

73

1870

Lawitz,
Mangia
et al7
2013

RCT

499

18+

18-70 y/o; Tx naïve;
Chronic HCV
genotype 1 infection;
[HCV RNA] ≥50,000
IU/mL; Adequate
hematologic and
biochemical
parameters
≥18 y/o; Tx naïve;
BMI of 18 kg/m;
Chronic genotype 2 or
3 HCV infection with
serum HCV RNA
≥10,000 IU/mL;
Subjects or their
partner(s) must be of
non-childbearing
potential or use
effective
contraception until 6
months after the last
dose of study
medication

Study

Inclusion Criteria

Exclusion Criteria

W/D

Interventions

Cirrhosis; HepB or
HIV infection

0

Cirrhosis; HepB or
HIV infection;
Psychiatric illness;
Pulmonary or cardiac
disease; Seizure
disorder or other
serious comorbid
disorders
HepB or HIV
infection; liver,
pulmonary, or cardiac
disease; psychiatric
illness, immunologic
disorder;
hemoglobinopathy;
seizure disorder or
anticonvulsant use,
poorly controlled
diabetes; cancer;
acute pancreatitis;
abnormal
hematologic &
biochemical
parameters

16

Sofosbuvir
400mg plus
Ribavirin (RBV)
VS. Sofosbuvir
400mg plus
RBV and
Peginterferon
(PEG)
Sofosbuvir
400mg plus
RBV and PEG
VS. Placebo plus
PEG and RBV

36

Sofosbuvir
400mg plus
RBV VS.
PEG plus RBV
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OUTCOMES MEASURED
In each of the three RCTs, safety was measured by self-reported adverse events, such as
fatigue and headache, and graded using the Division of AIDS Table for Grading the Severity of
Adult and Pediatric Adverse Events. All three studies determined efficacy by the sustained
virological response at 12 and 24 weeks post-treatment (SVR12 and SVR24, respectively),
which is classified by a HCV RNA concentration below the limit of detection of 15 IU/mL or 25
IU/mL, depending upon the lab used. For each trial, HCV RNA was quantified using the
COBAS AmpliPrep/COBAS TaqMan HCV Test. It has been shown that SVR12 and SVR24 are
highly correlated with virus eradication signifying no further need for treatment. Furthermore,
these endpoints greatly reduce HCV complications, including mortality, as well as decrease the
chance of a relapse.8

RESULTS
This systematic review assesses three RCTs for the efficacy and tolerability of Sofosbuvir
plus Ribavirin (RBV) compared to other modalities involving Peginterferon (PEG) for treatment
of chronic HCV infection. Each of the trials contained comparable study designs with
dichotomous data, which was used in intention-to-treat analysis. Additionally, all analysis was
performed with a 95% confidence interval (95% CI).
In the first study, Gane et al5 enrolled 21 patients with chronic HCV genotypes 2 and 3
into an open-label, active-controlled RCT. All 21 patients received 12 weeks of 400mg
Sofosbuvir plus RBV. 11 of the 21 patients were randomized to the control group, which
received 12 weeks of concurrent PEG treatment. Enrollees were followed for 24 weeks posttreatment. Every patient completed the trial and acquired sustained virological response (SVR)
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at 24 weeks post-treatment. With a 95% CI (69 to 100), statistical analysis of the experimental
group (experimental event rate, or EER) in comparison with the control group (control event
rate, or CER) revealed a relative benefit increase (RBI), an absolute benefit increase (ABI), and a
numbers needed to treat (NNT) of 0 (Table 2).
Gane et al5 also addressed the safety of treatment with Sofosbuvir and Ribavirin. The
most common self-reported adverse events during the trial were headache, fatigue, insomnia,
nausea, rash, and anemia. In regards to fatigue, 45% of patients in the control group (CER)
reported the symptom as opposed to 10% in the experimental group (EER). This resulted in a
calculated relative risk reduction (RRR) of -77.8%, an absolute risk reduction (ARR) of -35%,
and a number needed to harm (NNH) of -2 (Table 3). This negative NNH means that for every 2
patients treated, one fewer will experience the adverse event of fatigue in the experimental group
compared to the control group.
In Lawitz, Lalezari and colleagues6, a double-blind, placebo-controlled RCT, 48 patients
with HCV genotype 1 were assigned to the experimental group to receive treatment for 12 weeks
with 400mg Sofosbuvir, RBV, and PEG. 26 patients, placed in the control group, were allotted
to receive placebo, PEG, and RBV for 12 weeks. Of the 47 people who began treatment in the
experimental group and 26 who started in the control group, 42 and 14 people completed the
study, respectively. However, intention-to-treat analysis included everyone who began
treatment.
In the Sofosbuvir group, 89% of patients acquired sustained virological response (SVR)
at 24 weeks post-treatment (EER) as opposed to 58% of patients in the placebo group (CER). As
shown in Table 2, statistical analysis with a 95% CI (11 to 49) exposed a RBI of 58%, an ABI of
14%, and a numbers needed to treat (NNT) of 4. This positive NNT suggests that for every 4
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patients treated in the experimental group, one more will achieve SVR24 than compared to the
control group. Additionally, the p-value for the study equaled 0.0006 (Table 2).
The most common adverse events reported by Lawitz, Lalezari, et al6 were fatigue,
headache, nausea, and chills. Using fatigue for comparison, 68% in the experimental group
(EER) reported the symptom as opposed to 54% in the placebo group (CER). This resulted in a
RRR of 26%, an ARR of 14%, and a NNH of 8. This implies that for every 8 patients treated,
one more will have fatigue in the experimental group compared to the control group (Table 3).
In the third study, Lawitz, Mangia et al7 conducted an open-label, active-controlled RCT,
dubbed the FISSION study, using patients with HCV genotypes 2 and 3. Of the 499 patients
who started treatment, 256 underwent treatment in the experimental group with 400mg
Sofosbuvir plus RBV for 12 weeks. The other 243 patients, assigned to the control group,
received PEG and RBV for 24 weeks. All subjects who received at least one dose of study drug
were analyzed in the group to which they were randomized. Both the experimental and control
groups obtained an equal percentage of patients that acquired sustained virological response at
12 weeks post-treatment (SVR12). Since CER and EER were both 67%, statistical analysis
resulted in a RBI, ABI, and NNT of 0. A 95% CI (-7.5 to 8.0) and p-value of <0.001 were also
reported (Table 2).
Similar to the other two RCTs, the most self-reported adverse events in Lawitz, Mangia
et al7 were fatigue, headache, nausea, and insomnia. Using fatigue for calculations, 55.1% of
patients in the control group (CER) and 35.9% in the experimental group (EER) experienced this
adverse event. This resulted in a RRR of -34.8%, an ARR of -19.2%, and a NNH of -6, which
suggests that for every 6 patients treated, one fewer will experience the adverse event of fatigue
in the Sofosbuvir group compared to the control group (Table 3).
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Table 2: Efficacy of Treatment (Experimental vs. Control)
CER
EER
RBI
ABI
Study
NNT
(%)
(%)
(%)
(%)
Gane, et al5
Lawitz,
Lalezari, et al6
Lawitz,
Mangia, et al7

95% CI

p-value

100

100

0

0

0

69 to 100

-----

58

89

53

14

4

11 to 49

0.0006

67

67

0

0

0

-7.5 to 8.0

<0.001

Table 3: Adverse Event of Fatigue from Treatment (Experimental vs. Control)
Study

CER (%)

EER (%)

RRR (%)

ARR (%)

NNH (%)

Gane, et al5

45

10

-77.8

-35

-2

Lawitz, Lalezari, et al6

54

68

26

14

8

Lawitz, Mangia, et al7

55.1

35.9

-34.8

-19.2

-6

DISCUSSION
This systematic review compared three RCTs for the safety and efficacy of Sofosbuvir
and Ribavirin in the treatment of chronic HCV infection using participates who were 18 years of
ago or older with treatment-naïve chronic HCV genotypes 1, 2, or 3. In Gane et al5, a 12-week
regimen of Sofosbuvir plus RBV proved to be safer but just as effective as Sofosbuvir plus PEG
and RBV for treatment of chronic HCV genotypes 2 and 3. People with cirrhosis were excluded
from participating in this study. Cirrhosis has been associated with a reduced response to
treatment, thus results may be skewed. Furthermore, the sample size of both the experimental
and control groups were both small at 10 and 11 participants, respectively. Results, then, may be
insufficient.
Lawitz, Lalezari and colleagues6 examined the chronic HCV genotype 1 treatment
regimen of Sofosbuvir 400mg plus PEG and RBV in comparison to placebo, PEG, and RBV for
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12 weeks. Results show that Sofosbuvir-PEG-RBV was more effective yet had more adverse
events than the control group. It should be noted that most of the adverse events in the
experimental group, such as that of fatigue, were noticed during treatment with PEG and RBV as
opposed to Sofosbuvir. As with Gane et al5, people with cirrhosis were excluded from
participating in the study which could have altered the results.
In the 3rd study, Lawitz, Mangia et al7, the 12-week regimen of Sofosbuvir plus RBV
showed fewer adverse events but equal efficacy to PEG-RBV for treatment of HCV genotypes 2
and 3. In this study, 20% and 21% of participants in the experimental and control groups,
respectively, had cirrhosis, which affected treatment efficacy and incidence of adverse events.
Furthermore, efficacy was only measured to week 12 post-treatment (SVR12), which, although
sufficient, could have been measured to week 24 (SVR24) for better results.
In regards to safety, the author chose to only address one of the most common selfreported adverse events, making it an outcome that directly affects the patient, or rather, patientoriented evidence that matters (POEM). It is known, however, that treatment with PEG can
cause hematologic anomalies such as cytopenia.5 It should be noted that this was seen in each of
the three RCTs when participants were treat with PEG. Furthermore, in the large cohort
FISSION study in Lawitz, Mangia et al7 it was discovered that “adverse events associated with
various organ systems” were consistently higher in the PEG-RBV control group as opposed to
the experimental group of Sofosbuvir-RBV.7
Overall, Sofosbuvir, itself, has been well tolerated in all clinical trials, thus far. Potential
drug interactions include certain anticonvulsants, antimycobacterials, HIV protease inhibitors,
and the herbal supplement St. John's wort. 9 Each of these interactions may decrease the level of
available Sofosbuvir. It has also been discovered that Sofosbuvir has a high genetic barrier for
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resistance, meaning that, unless there are many crucial genetic mutations, it should remain an
effective treatment. The biggest downside to Sofosbuvir, which was only recently FDA
approved in December 2013, is that it costs a staggering $1,000 for one 400mg pill, resulting in a
total cost of $84,000 after completion of a 12-week course.9 Although highly effective, efficient,
and safe, the elated price may deter insurance companies or individuals from covering the
treatment.
CONCLUSION
In conclusion, it can be deduced that Sofosbuvir plus RBV is safer, yet, statistically,
nearly equal in efficacy to treatment with PEG and RBV. Given that PEG is a weekly
subcutaneous injection with many side effects, it would be more beneficial to receive treatment
with Sofosbuvir.
While each RCT carried similar results, future large cohort studies should be done with
standardized parameters such as using one specific genotype or fully excluding or including
participants with cirrhosis. Although the RCTs included smaller analyses that addressed these
variations, the primary end points of safety and efficacy included all patients. Additionally, to
further confirm efficacy in each RCT and rule out relapse of HCV, a one-year post-treatment
SVR measurement should be done.
Each of these three RCTs examined additional treatment regimens besides the
experimental and control groups. Such alterations included a different dose of Sofosbuvir or
varying amounts of PEG treatments. For commonality’s sake, the author of this systematic
review chose the most suitable comparison groups. With that said, the only RCT that
specifically contrasted the treatment of Sofosbuvir and RBV with that of PEG and RBV was
Lawitz, Mangia, et al7. Although this study had the largest cohort, it compared treatment with
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the experimental group for 12 weeks versus 24 weeks for the control group. One might argue
that given a reduced treatment time of 12 weeks, the results would have pointed in favor of
Sofosbuvir plus RBV for the best efficacy. Additionally, the study observed treatment in
patients with genotypes 2 and 3, rather than the more common genotype 1 HCV infection.
Therefore, for a more accurate analysis, another RCT could be performed comparing 12 weeks
of Sofosbuvir and RBV treatment with 12 weeks of PEG and RBV in patients with genotype 1
HCV infections.
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